CClinicalTrials.gg
CompletedNCT04016103Updated Feb 21, 2024

MY01 - An Aid for Diagnosing Acute Compartment Syndrome in Real Time

An interventional study of MY01 - Continuous Compartmental Pressure Monitor in Acute Compartment Syndrome, sponsored by MY01 Inc.. Completed at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by MY01 Inc. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Compartment syndrome can result from extremity trauma. It can also be caused by procedural cases that involve lower or upper extremity surgery. This condition results in muscle death, chronic pain, infection, and possible amputation. Early diagnosis is essential to institute interventions that can avoid complications. Subjective pain of the patient remains the mainstay for diagnosis. A method or device is needed that would improve our accuracy in diagnosing compartment syndrome. Ideally, this would be suited for single and/or continuous pressure read-outs. The aim is to reduce the incidence of missed compartment syndrome and diminish delays that would lead to significant disability.

Despite awareness, delayed diagnosis and treatment occurs in modern orthopaedic practice. As noted in many studies, once a diagnosis has been made, immediate fasciotomy is necessary to provide the best chance for a favourable clinical result. Therefore, there is a need for improved devices in order to obtain an early and reliable diagnosis.

02

Conditions studied

  • Acute Compartment Syndrome

Keywords

  • Acute Compartment Syndrome
03

In context

Compartment Syndromes

75 studies on the registry are indexed under Compartment Syndromes; 12 are open to participants now.

This study's enrollment of 50 is close to the median of 50 across 43 interventional studies indexed under Compartment Syndromes.

Browse Compartment Syndromes studies →

Lead sponsor

MY01 Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men or women, aged 18 years of age and older
  • Any tibial, foot, femoral, forearm or fracture that is felt by the surgeon to have a reasonable indication that elevated ICP could occur in the patient
  • Mentally fit to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients with fractures that are not felt to be at risk of developing compartment syndrome based on serial clinical evaluation
  • Infected wounds; infected fractures
  • Patients who present with ACS requiring urgent surgical fasciotomy
  • Patients who cannot consent to trial
  • Pregnant women
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    MY01 Device

    Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure

    Device: MY01 - Continuous Compartmental Pressure Monitor

Interventions

  • DeviceMY01 - Continuous Compartmental Pressure Monitor

    Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure

06

What researchers measure

Primary outcomes

  1. Clinical ease with which the new compartment pressure monitor was inserted into compartment.

    At device insertion, the physician will complete a feedback questionnaire, and routine assessment will be performed in compliance with the standard of care. As part of the feedback questionnaire, the physician will be asked to indicate on a sliding scale "How certain are you the device functioned adequately?" \[0 = not confident\] - \[10 = very confident\]. The scale, administered part of a Clinical Report Form (CRF) titled 'Physician Survey', measures the physicians subjective level of certainty that the device sensor was inserted correctly within a patients muscle compartment. A record of 10 should be considered a very positive scenario, whereas a record of 0 should indicate a very negative scenario.

    Time frame: 24-48 hours following device insertion

  2. Ability to monitor in real-time the continuous pressure read-out from the compartment in remote locations such as an I-phone.

    At device insertion, the physician will complete a feedback questionnaire, and routine assessment will be performed in compliance with the standard of care. As part of the feedback questionnaire, the physician will be asked to indicate in a Yes or No question "Did the MY01 Application remote data display work properly?" \[Yes\] or \[No\].

    Time frame: 24-48 hours following device insertion

  3. The correlation of continuous pressure read-outs (high, normal or low) with clinical indications for compartment syndrome in each patient.

    Routine assessments will be completed by healthcare personnel as per standard of care (the 6P's \[Pain, Paraesthesia, Pallor, Paralysis, Pulselessness, Poikilothermia\]), and compared against the pressure readout \[mmHG\] indicated by MY01's MicroElectroMechanical (MEMS) pressure sensor inserted at the afflicted location.

    Time frame: 24-48 hours following device insertion, and again during the final follow-up of the participant approximately two weeks after treatment

Secondary outcomes

  1. Correlation of clinical compartment syndrome release with data from the continuous pressure monitor read-out.

    Should surgical fasciotomy be deemed necessary to release pent up pressure in the patients muscle compartment, the continuous pressure read-outs \[mmHG\] derived from the device will be compared against the timeframe when the decision to conduct fasciotomy was made.

    Time frame: 24-48 hours following device insertion, and again during the final follow-up of the participant approximately two weeks after treatment

  2. Short-term outcomes of the patient following continuous pressure monitoring

    Survey and tabulation of data from patient clinical findings.

    Time frame: 24-48 hours following device insertion.

07

Study locations

2 sites
  • Montreal General Hospital
    Montreal, Quebec H3G 1A4, Canada
  • Hôpital du Sacré-Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04016103
Lead sponsor
MY01 Inc.
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre, Hopital du Sacre-Coeur de Montreal
Responsible party
Sponsor
First posted
Jul 11, 2019
Start date
Jul 17, 2020
Primary completion
Feb 1, 2023
Completion
Jun 30, 2023
Last update
Feb 21, 2024

Study contacts

Mitchell Bernstein, MD
principal investigator · Staff Surgeon, Orthopaedic Trauma & Limb Deformity, Montreal General Hospital | Assistant Professor Department of Surgery and Pediatric Surgery McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion